Janux Therapeutics, Inc. (JANX) News
Follow Janux Therapeutics, Inc. (JANX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Wolfe Research upgrades JANX to Outperform, sets $23 target
Wolfe Research upgrades JANX from Peerperform to Outperform and assigns a $23.00 price target, with no catalyst supplied in the alert.
EQUITY | Aug 24, 2026, 11:59 AM UTC
L
Analysts raise ratings on ALGT, CLS, DRI, JANX and PHM
A wire item says analysts upgraded ALGT to Strong Buy at Raymond James, CLS to Buy at UBS, and DRI, JANX and PHM to Outperform at Baird or Wolfe.
EQUITY | Aug 24, 2026, 10:50 AM UTC
L
Wolfe Research upgrades JANX to Outperform, sets $23 target
Wolfe Research upgrades JANX to Outperform from Peerperform and sets a $23 price target.
EQUITY | Aug 24, 2026, 10:15 AM UTC
M
JANX: Truist Assumes Buy
Truist Securities analyst assumes Janux Therapeutics with a Buy rating and lowers Price Target to $26
EQUITY | Jun 25, 2026, 02:10 PM UTC